obefazimod

Small molecule

Also known as ABX464

Reliablesignal

Evidence outlook · lead readout

ABTECT - Maintenance (NCT05535946) · Ulcerative Colitis

The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.

ABTECT - Maintenance (NCT05535946): This trial randomized responder patients to obefazimod 25 mg, 50 mg, or placebo under triple-blind conditions, with a large sample size (over 1,100 participants enrolled across the program), and its primary endpoint was clinical remission, a hard, disease-defining measure of ulcerative colitis activity. The comparison clearly favored obefazimod over placebo with a large effect size and high statistical significance, meeting all the elements needed for strong evidence: real randomization, blinding, an adequately sized placebo control, a hard clinical endpoint, and a statistically significant favorable result.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Crohn's Disease · Phase 2

Company guidance: regulatory filing expected by the end of 2026 (Abivax, 30 Jul 2026). “Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2026” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Ulcerative Colitis
Phase 2/3 (2)
Crohn's Disease
NCT03905109 · Abivax S.A.
2022-09-19 – 2022-09-19 · Crohn Disease
What this study did
Other / comorbidity
NCT04393038 · Abivax S.A.
2020-07-01 – 2021-04-16 · COVID-19
What this study did
Phase 2 (10)
Crohn's Disease
Ulcerative Colitis
NCT05177835 · Abivax S.A.
2021-12-03 – 2028-04 · Ulcerative Colitis
What this study did
NCT04023396 · Abivax S.A.
2020-01-13 – 2023-02-23 · Ulcerative Colitis
What this study did
NCT03368118 · Abivax S.A.
2018-01-20 – 2022-08-15 · Ulcerative Colitis
What this study did
NCT03760003 · Abivax S.A.
2019-08-13 – 2021-04-16 · Ulcerative Colitis
What this study did
NCT03093259 · Abivax S.A.
2017-11-16 – 2019-02-04 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT04049448 · Abivax S.A.
2019-10-25 – 2023-01-23 · Rheumatoid Arthritis
What this study did
NCT03813199 · Abivax S.A.
2019-07-04 – 2021-04-27 · Rheumatoid Arthritis
What this study did
NCT02735863 · Abivax S.A.
2016-05 – 2018-01-11 · HIV Infection
What this study did
NCT02452242 · Abivax S.A.
2015-01 – 2016-05 · Human Immunodeficiency Virus Infections
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT02990325 · Abivax S.A.
2017-03-27 – 2019-10-21 · HIV Infections, Health Volunteers
What this study did
Phase 1 (5)
Other / comorbidity
NCT07453784 · Abivax S.A.
2026-03-03 – 2027-04 · Healthy
What this study did
NCT05032560 · Abivax S.A.
2021-09-27 – 2022-02-18 · Healthy Volunteers
What this study did
NCT05121714 · Abivax S.A.
2020-12-17 – 2021-05-18 · Healthy
What this study did
NCT02731885 · Abivax S.A.
2014-09 – 2015-06 · Healthy Volunteers
What this study did
NCT02792686 · Abivax S.A.
2014-03 – 2014-07 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Crohn's Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Obefazimod: this drugPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 11 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow obefazimod to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Crohn's DiseaseRecruiting
Est. primary completion 2026-12 · NCT06456593 · CT.gov ↗
What to watch
2027 (1)
April 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-04 · NCT07453784 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 2Ulcerative ColitisActive not recruiting
Est. primary completion 2028-03 · NCT05177835 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026Topline resultPhase 3 ABTECT maintenance trial of obefazimod met the primary endpoint (clinical remission at Week 44); NDA planned for late Q4 2026
Abivax · Source ↗
22 July 2025Topline resultPhase 3 ABTECT-1 and ABTECT-2 induction trials of obefazimod met the primary endpoint (clinical remission at Week 8, 50 mg)
Abivax · Source ↗